MV

@MVAS52

Private Investor & very part time Pharmacist - (Hold a B.S. in Pharmacy, but follow at your own risk and please make your own investment/trading decisions).

Southern part of USA
Vrijeme pridruživanja: ožujak 2013.

Tweetovi

Blokirali ste korisnika/cu @MVAS52

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MVAS52

  1. prije 11 sati

    Let the comical comments begin - seems like there is always someone that thinks a Secondary cash raise is evil, ugly, or downright criminal....was Coop also Impeached or what? But acquitted by Friday! I am over it already. Might be the last cash raise they ever need.

    Poništi
  2. prije 15 sati

    That's all in here >(quotes), recent 424B5 Form from >>>

    Prikaži ovu nit
    Poništi
  3. prije 15 sati

    Remember sometime last year, he said that Allogenic BMT type trial would be easier to gain first IND on, & felt like it was a great indication to target from experience but that they would still go after the autologous indication after, was my understanding. IV going crazy.

    Prikaži ovu nit
    Poništi
  4. prije 15 sati

    Most likely they do that Autologous type CD19 RPM CarT trial too; they said they would pursue it > "We are also advancing our RPM technology including using patient-derived (autologous) T cells to treat patients with relapsed or refractory CD19+ leukemias and lymphomas."

    Prikaži ovu nit
    Poništi
  5. prije 15 sati

    This would be the new CD19 RPM CarT trial (old one was for autologous - likely too old to use)> "In this trial, we plan to infuse donor-derived T cells after allogeneic bone marrow transplantation, or BMT for recipients who have relapsed with CD19+ leukemias & lymphomas."

    Prikaži ovu nit
    Poništi
  6. prije 18 sati

    Pretty much wiped out most of all 2019 stock price gains; if this was 2019 we would only be up a Buck. My biggest complaint is not stock price, cause I am nearly 100% sure data ahead will prove its worth, across 3 solid platforms. You have to look forward not backwards.

    Prikaži ovu nit
    Poništi
  7. prije 18 sati

    605.5M right now, before the shares add on.

    Prikaži ovu nit
    Poništi
  8. prije 18 sati

    More than cut in half since last year's summer high of $7.25 - company could end up with $100 Million more funds with the same (or less) Valuation as before raising the funds. More data than ever before upcoming & more advanced Human Clinical trials too. Added.

    Prikaži ovu nit
    Poništi
  9. prije 19 sati

    "In a joint venture with TriArm Therapeutics, Ltd. or TriArm, we formed Eden BioCell, Ltd., or Eden BioCell, to lead the clinical development and commercialization of Sleeping Beauty-generated CD19-specific RPM CAR-T therapies in the People’s Republic of China, Taiwan and Korea."

    Prikaži ovu nit
    Poništi
  10. prije 19 sati

    Not DEAD! Maybe try another Lie? "We are also advancing our RPM technology including using patient-derived (autologous) T cells in order to treat patients ...... In a JV with TriArm Therapeutics, Ltd., or TriArm, we have formed Eden BioCell, Ltd."

    Prikaži ovu nit
    Poništi
  11. prije 19 sati

    "....in the United States infusing CD19-specific CAR+ T therapies manufactured using our RPM technology. In this trial we plan to infuse donor-derived T cells after allogeneic bone marrow transplantation, or BMT, for recipients who have relapsed with CD19+ leukemias & lymphomas."

    Prikaži ovu nit
    Poništi
  12. prije 19 sati

    If Ziopharm SB CarT is dead, (like one poster wants you to think) then how come this is in the current SEC Filing Prospectus?> "We are advancing our CAR+ T technology in the United States in collaboration with MDA in a Phase 1 clinical trial ...."

    Prikaži ovu nit
    Poništi
  13. prije 21 sat

    Either updated soon, or they could be negotiating a deal/sale of that asset? Just a guess, & would be a big "wildcard" that not many are thinking will occur.

    Prikaži ovu nit
    Poništi
  14. prije 21 sat
    Prikaži ovu nit
    Poništi
  15. prije 21 sat

    Updated today - so likely some coming Activity of a "New Trial" to be posted soon. It would be this: Patients w/ CD19+ leukemias & lymphomas who have relapsed after allogeneic bone marrow transplantation will be enrolled to evaluate infusion of donor-derived RPM CAR-T.

    Prikaži ovu nit
    Poništi
  16. prije 21 sat

    ....Already told us, that this would not be their "first" Indication for the "New" trial for "2 days" mbIL15 RPM CD19 CarT {Withdrawn (Study was not activated and there were no participants treated on study)}

    Prikaži ovu nit
    Poništi
  17. prije 21 sat

    ***Per this = Fast closing = Spot Ziopharm said it expects to see proceeds of $90.4 million.... said it intends to use the proceeds for progressing its clinical programs towards commercialization,...etc. The offering is expected to close on or about Feb. 7.*** Dow Jones

    Poništi
  18. prije 23 sata

    All red 5 min candles so far since the open - nice effort by these goons! Will wait for much lower before adding; can't put it past these psychotic jerks for sure! (as always). But eventually this stock bounces back hard.

    Prikaži ovu nit
    Poništi
  19. prije 23 sata

    Must be no secrets? Someone in the know, knew of the Ziopharm spot secondary, so dumped Precigen down, thinking it would affect Precigen? PGEN does not need cash, but who knows - would they raise cash? Have some $180 Million now on hand?

    Poništi
  20. prije 23 sata

    Shorts fighting it as usual; but this is a done deal, so...... {wonder if they just wait for data to finally cover?} Will this end up being the first FEB for Ziopharm to be down, for first time since 2012? Not getting my shares either way.

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·